Nongenomic activity and subsequent c-fos induction by estrogen receptor ligands are not sufficient to promote deoxyribonucleic acid synthesis in human endometrial adenocarcinoma cells.

Abstract	Estrogen 17beta-estradiol (E2) rapidly modulates several signaling pathways related to cell growth, preservation, and differentiation. The physiological role of these nongenomic effects with regard to downstream outcomes, and the relationship with transcriptional estrogen activity are unclear. Furthermore, the ability of selective estrogen receptor modulators (SERMs) to trigger nongenomic actions is largely unknown. To determine whether estrogen receptor (ER) ligands exert nongenomic activity in endometrial adenocarcinoma cells, and whether this activity affects transcription and DNA synthesis, we challenged human Ishikawa cells with E2 or partial ER agonists 4-hydroxytamoxifen (OHT) and raloxifene (ral). Serum-starved Ishikawa cells exposed for 5 min to 0.1 nM E2 showed induced phosphorylation of MAPK (ERK1/2). Ral and 4-OHT each at 1 nM also stimulated ERK in a rapid transient manner. E2 and 4-OHT induced proto-oncogene c-fos mRNA expression in Ishikawa cells within 30 min, but ral had no effect. In contrast to nongenomic action, only E2 stimulated expression of an estrogen response element (ERE)-driven luciferase (LUC) reporter gene. To examine DNA synthesis, [(3)H]-thymidine incorporation was measured in serum-starved cultures exposed to E2 or partial agonists for 2 d. E2 at 1 nM stimulated thymidine uptake in an ERK-dependent manner, but 1 nM 4-OHT, 1 nM ral, and 0.1-nM concentrations of E2 had no significant effects. Taken together, these data indicate that both nongenomic and direct transcriptional ER effects are likely required to promote DNA synthesis.
Authors	David W Singleton, Yuxin Feng, Craig J Burd, Sohaib A Khan
Journal	Endocrinology (Endocrinology) Vol. 144 Issue 1 Pg. 121-8 (Jan 2003) ISSN: 0013-7227 [Print] United States
PMID	12488337 (Publication Type: Journal Article, Research Support, U.S. Gov't, Non-P.H.S., Research Support, U.S. Gov't, P.H.S.)
Chemical References	Estrogen Receptor alpha Estrogen Receptor beta MAS1 protein, human Proto-Oncogene Mas Proto-Oncogene Proteins c-fos Receptors, Estrogen Recombinant Fusion Proteins Tamoxifen afimoxifene Raloxifene Hydrochloride Estradiol DNA Luciferases Mitogen-Activated Protein Kinase 1 Mitogen-Activated Protein Kinase 3 Mitogen-Activated Protein Kinases
Topics	Adenocarcinoma (metabolism) DNA (biosynthesis) Endometrial Neoplasms (metabolism) Enzyme Activation (drug effects) Estradiol (pharmacology) Estrogen Receptor alpha Estrogen Receptor beta Female Gene Expression (drug effects) Humans Luciferases (genetics) Mitogen-Activated Protein Kinase 1 (metabolism) Mitogen-Activated Protein Kinase 3 Mitogen-Activated Protein Kinases (metabolism) Mutation Proto-Oncogene Mas Proto-Oncogene Proteins c-fos (genetics) Raloxifene Hydrochloride (pharmacology) Receptors, Estrogen (agonists, genetics, physiology) Recombinant Fusion Proteins Response Elements Tamoxifen (analogs & derivatives, pharmacology) Transfection Tumor Cells, Cultured

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!